Previous 10 | Next 10 |
IDEAYA Biosciences to Participate in Investor Conferences in May 2022 PR Newswire SAN FRANCISCO , May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the disco...
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma PR Newswire - Darovasertib designated as an Orphan Drug by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, an...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Ideaya Biosciences' (NASDAQ:IDYA) darovasertib to treat uveal melanoma (UM). UM is rare cancer that starts in the cells that make the dark-colored pigment called melanin, in the uvea or uveal tract of the...
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with this event. For further details see: IDEAYA Biosciences (IDYA) Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors PR Newswire - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories SOUTH SAN FRANCISCO, Ca...
IDEAYA Biosciences, Inc. (IDYA) Q4 2021 Earnings Conference Call March 15, 2022 08:30 AM ET Company Participants Yujiro Hata - Chief Executive Officer & President Matt Maurer - Head, Clinical Oncology Michael White - Chief Scientific Officer Paul Stone - Chief Financial Officer Conference...
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: IDEAYA Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: IDEAYA Biosciences, Inc. 2021 Q4 - Results - Earnings Call Presentation
IDEAYA Biosciences press release (NASDAQ:IDYA): Q4 GAAP EPS of -$0.47 misses by $0.16. Revenue of $2.96M (-72.1% Y/Y) misses by $6.02M. For further details see: IDEAYA Biosciences GAAP EPS of -$0.47 misses by $0.16, revenue of $2.96M misses by $6.02M
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update PR Newswire - Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of December 31, 2021 is anticipated to fund planned operations into 2025 ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...